Loading filters...
50 results(scroll for more)
MRD DetectionAll Contexts2026
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.
Zhou J et al. Int J Cancer. 2026
Early Cancer DetectionAll Contexts2026
Liquid biopsies in precision oncology for older adults with cancer.
Zhao Y et al. NPJ Precis Oncol. 2026
ctDNA Detection MethodsAll Contexts2026
Peritoneal lavage fluid minimal residual cancer cells detection for early prediction of peritoneal metastasis in gastric cancer: A multi-cohort validation study.
Yue P et al. Int J Cancer. 2026
ctDNA Detection Methodsadvanced2026
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
Vlachos G et al. Br J Cancer. 2026
ctDNA Detection Methodsadvanced2026
Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.
Widjaja AO et al. Int J Cancer. 2026
ctDNA Detection MethodsAll Contexts2026
Comparative Analysis of TP53-Mutated Tumor DNA in Saliva and Plasma of Patients with Head and Neck Squamous Cell Carcinoma.
Kampel L et al. J Mol Diagn. 2026
ctDNA Detection Methodsadvanced2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.
Topham JT et al. Clin Cancer Res. 2026
ctDNA Detection Methodsearly2026
ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
Dyrskjøt L et al. Ann Oncol. 2026
ctDNA Detection Methodsadvanced2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.
Stutheit-Zhao EY et al. NPJ Precis Oncol. 2026
Technology/Platformsadvanced2026
Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.
Stevens M et al. Mol Oncol. 2026
Technology/PlatformsAll Contexts2026
ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.
Solé L et al. Br J Cancer. 2026
Postoperative Surveillanceearly2026
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.
Franken IA et al. Eur J Cancer. 2026
Technology/PlatformsAll Contexts2026
Detection and classification of lymphoma from cell-free methylome data.
Shelton VB et al. NPJ Precis Oncol. 2026
Prognostic Valueadvanced2026
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.
Ros J et al. ESMO Open. 2026
Technology/Platformsadvanced2026
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.
Botticelli A et al. Clin Cancer Res. 2026
Technology/PlatformsAll Contexts2026
On the Road to ROME: Defining Tissue-Liquid Concordance in Precision Oncology.
Saldanha EF et al. Clin Cancer Res. 2026
Prognostic ValueAll Contexts2026
Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma.
Robic V et al. Eur J Cancer. 2026
Early Cancer DetectionAll Contexts2026
Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow-up biomarkers for breast cancer.
Rajan N et al. Mol Oncol. 2026
ctDNA Detection Methodsadvanced2026
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.
Ciracì P et al. Ann Oncol. 2026
Prognostic Valueadvanced2026
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
Jayaram A et al. Nat Cancer. 2026
MRD DetectionAll Contexts2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.
Provencio M et al. Clin Cancer Res. 2026
ctDNA Detection Methodsadvanced2026
Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer.
Pretz C et al. NPJ Precis Oncol. 2026
Early Cancer Detectionearly2026
Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium.
Worthington C et al. Int J Cancer. 2026
Prognostic Valueadvanced2026
Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.
Piperno-Neumann S et al. Ann Oncol. 2026
Resistance DetectionAll Contexts2026
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
Dieci MV et al. Eur J Cancer. 2026
ctDNA Detection MethodsAll Contexts2026
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D et al. Clin Cancer Res. 2026
Prognostic Valueadvanced2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.
Voorthuis RAB et al. Clin Cancer Res. 2026
MRD Detectionadvanced2026
Unveiling personalised targets of PD-1 blockade hyperprogression in a cervical adenocarcinoma via longitudinal single-cell and spatial monitoring.
Su Z et al. NPJ Precis Oncol. 2026
ctDNA Detection Methodsadvanced2026
Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.
Sanz-Garcia E et al. Clin Cancer Res. 2026
ctDNA Detection MethodsAll Contexts2026
Nanoplate based digital PCR assay for effective quantification of plasma HPV circulating tumor DNA.
Parida P et al. NPJ Precis Oncol. 2026
ctDNA Detection MethodsAll Contexts2026
Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma.
Park CL et al. Clin Cancer Res. 2026
Methylation AnalysisAll Contexts2026
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors.
Smith KS et al. Nat Cancer. 2026
Postoperative SurveillanceAll Contexts2026
Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection.
Oyoshi H et al. NPJ Precis Oncol. 2026
ctDNA Detection Methodsadvanced2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.
Zhou M et al. NPJ Precis Oncol. 2026
ctDNA Detection Methodsadvanced2026
Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer.
Nishizaki D et al. NPJ Precis Oncol. 2026
Prognostic Valueearly2026
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
Necchi A et al. J Clin Oncol. 2026
ctDNA Detection Methodsearly2026
Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.
Nakamura Y et al. NPJ Precis Oncol. 2026
Prognostic Valueearly2026
A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy.
Piumatti E et al. Mol Oncol. 2026
ctDNA Detection Methodsadvanced2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.
Paracchini L et al. ESMO Open. 2026
Technology/PlatformsAll Contexts2026
Pitfalls in detecting MET exon 14 skipping variants by DNA- and RNA- based next generation sequencing technologies in a large real-world cohort and results of the first multinational EQA schemes.
Heydt C et al. J Mol Diagn. 2026
Prognostic Valueadvanced2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Mellema JJ et al. Nat Med. 2026
Prognostic ValueAll Contexts2026
An international framework for clinical translation of molecular classifiers in osteosarcoma.
Marinoff AE et al. NPJ Precis Oncol. 2026
Technology/PlatformsAll Contexts2026
Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.
Lopes CDH et al. NPJ Precis Oncol. 2026
ctDNA Detection MethodsAll Contexts2026
Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy.
Liu J et al. Cancer Res. 2026
ctDNA Detection Methodsearly2026
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung Cancer.
Lei S et al. JCO Precis Oncol. 2026
Technology/Platformsadvanced2026
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network.
La Porte P et al. JCO Precis Oncol. 2026
Prognostic Valueearly2026
Pretreatment KRAS-Mutant Circulating Tumor DNA Predicts Incidence and Patterns of Recurrence in Patients Undergoing Radiofrequency Ablation for Colorectal Liver Metastases: A Prospective Analysis.
Lin K et al. JCO Precis Oncol. 2026
ctDNA Detection MethodsAll Contexts2026
Translational feasibility of a plasmonic microarray-based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer.
Lee JY et al. NPJ Precis Oncol. 2026
Prognostic ValueAll Contexts2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
Katims AB et al. Clin Cancer Res. 2026
ctDNA Detection MethodsAll Contexts2026
Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions.
Kagami LAT et al. NPJ Precis Oncol. 2026